BidaskClub cut shares of GenMark Diagnostics (NASDAQ:GNMK) from a hold rating to a sell rating in a research report released on Friday morning.
A number of other research firms also recently issued reports on GNMK. Zacks Investment Research downgraded shares of GenMark Diagnostics from a hold rating to a sell rating in a research note on Wednesday, October 17th. Canaccord Genuity decreased their price target on shares of GenMark Diagnostics from $10.00 to $9.00 and set a buy rating for the company in a research note on Tuesday, October 30th. ValuEngine raised shares of GenMark Diagnostics from a sell rating to a hold rating in a research note on Friday, November 2nd. Finally, Raymond James set a $7.00 price target on shares of GenMark Diagnostics and gave the stock a buy rating in a research note on Thursday, December 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $9.50.
Shares of NASDAQ:GNMK opened at $5.85 on Friday. The stock has a market cap of $325.10 million, a PE ratio of -4.83 and a beta of 1.49. The company has a quick ratio of 3.10, a current ratio of 3.75 and a debt-to-equity ratio of 0.69. GenMark Diagnostics has a 12 month low of $3.58 and a 12 month high of $8.81.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. OLD National Bancorp IN grew its holdings in GenMark Diagnostics by 5.9% in the fourth quarter. OLD National Bancorp IN now owns 48,475 shares of the medical equipment provider’s stock worth $236,000 after purchasing an additional 2,700 shares during the period. Granite Investment Partners LLC grew its holdings in GenMark Diagnostics by 11.2% in the third quarter. Granite Investment Partners LLC now owns 111,905 shares of the medical equipment provider’s stock worth $823,000 after purchasing an additional 11,280 shares during the period. MetLife Investment Advisors LLC grew its holdings in GenMark Diagnostics by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 40,896 shares of the medical equipment provider’s stock worth $301,000 after purchasing an additional 14,546 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in GenMark Diagnostics in the fourth quarter worth about $84,000. Finally, Bank of New York Mellon Corp grew its holdings in GenMark Diagnostics by 7.5% in the fourth quarter. Bank of New York Mellon Corp now owns 232,611 shares of the medical equipment provider’s stock worth $1,130,000 after purchasing an additional 16,279 shares during the period. Institutional investors and hedge funds own 97.93% of the company’s stock.
About GenMark Diagnostics
GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.
Recommended Story: Trading signals using Bollinger bands
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.